ArticleJournal of translational medicine2026
Exosomal lncRNA SILC1 from bicalutamide-activated mesenchymal stem cells promotes prostate cancer survival and bicalutamide resistance via the miR-577/RHOA axis.
Article in Journal of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
backgroundThe development of resistance to anti-androgen therapies, such as bicalutamide (Bic), poses a significant challenge in the treatment of prostate cancer (PCa), and the intercellular complex mechanisms are difficult to comprehend. Emerging evidence suggests that stem cells and their secreted exosomes (Exo) contribute to tumor microenvironment-mediated drug resistance. However, the role of these vesicles in promoting bicalutamide resistance in prostate cancer remains elusive. This work aimed to clarify the mechanism by which exosomes from bicalutamide-stimulated mesenchymal stem cells (Bic-MSCs-Exo) provide resistance to bicalutamide in prostate cancer.
methodsThis work aimed to clarify the function of exosomes produced from Bic-MSCs in bicalutamide resistance in PCa and its molecular underpinnings. The impact of Bic-MSCs supernatants and their exosomes on cell proliferation, clone formation, migratory capacity, and apoptosis was assessed by the co-culturing of these supernatants and exosomes with PCa cells to elucidate their pro-resistance phenotype. Additional short RNA sequencing of exosomes, together with bioinformatics and single-cell data analysis, was conducted to identify and characterize the pivotal molecule lncRNA SILC1. The downstream regulatory network was validated by dual-luciferase reporter assays, functional rescue and loss-of-function tests, quantitative PCR, and Western blotting; the molecular processes were confirmed at both the in vivo and clinical levels using an organoid model and clinical samples analyzed via FISH.
resultsWe found that Bic-MSCs-derived exosomes (Bic-MSCs-Exo) promote prostate cancer (PCa) cell survival and drug resistance. Using sequencing and quantitative PCR (qPCR) analyses, we found that exosomes carry the drug-resistant molecule SILC1, which binds miR-577 and functions as a competing endogenous RNA (ceRNA). Combining multi-database analyses with experimental data, we confirmed that miR-577 targets and inhibits RHOA expression. Notably, high expression levels of RHOA are associated with increased proliferation, invasion, and enhanced clonogenic ability in prostate cancer cells. Furthermore, we demonstrated that the knockdown of SILC1 leads to the downregulation of RHOA. In organoid models of hormone-sensitive prostate cancer (HSPC) and Castration-Resistant Prostate Cancer (CRPC), it was found that RHOA was considerably overexpressed in CRPC. Additionally, a fluorescence in situ hybridization (FISH) study of clinical specimens demonstrated a link among the expression of SILC1, miR-577, and RHOA.
conclusionsThe discovery of the lncRNA SILC1 /RHOA as a promising marker of PCa resistance sheds light on the molecular pathogenesis of PCa resistance and provides potential therapeutic targets for the disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.